Filing Flows

Filing Flows › Hinge Health (HNGE) › Q3 2026

Hinge Health (HNGE) Q3 2026 earnings results (third quarter 2026)

8-K filed Nov 2, 2026

Hinge Health (HNGE) reported revenue of $235M for the third quarter 2026 (Q3 2026), +52% from a year earlier and +10% from the quarter before. Operating margin was 21.4%, net earnings $57.4M (24.4% of revenue).

Revenue$235M
Year over year+52%
Quarter over quarter+10%
Operating margin21.4%
Net earnings$57.4M

Hinge Health, Q3 2026: revenue $235M (+52% year over year), operating margin 21.4%, net earnings $57.4M, operating cash flow $115M. The chart follows the revenue to costs, profit and cash.

Q3 2026AmountQ/QY/Y
Revenue$235M+10%+52%
Gross profit$204M+11%+62%
Operating profit$50.3M+24%—
Net earnings$57.4M+31%—
Operating cash flow$115M+13%+39%
Free cash flow$113M—+39%

What changed

Revenue was $235.0M in Q3 2026, up 52% year over year and up 10% from the previous quarter.

Gross margin was 87.0%, up 5.1 points from Q3 2025. Operating profit was $50.3M, a 21.4% margin (up 25.4 points year over year). Operating expenses grew 16% against revenue growth of 52%. The fastest-growing cost line was Sales & marketing (+34%). Net earnings were $57.4M. The effective tax rate was -6.9%.

Operating cash flow was $114.6M (up 39% year over year), 200% of net earnings. Non-cash charges added back $2.2M of depreciation and amortization and $19.5M of share-based compensation. Working capital and other items added $35.4M. After purchases of property, equipment and software (including capitalized internal use software) ($1.9M), free cash flow as the company reports it was $112.7M.

Questions

What was Hinge Health's revenue in the third quarter 2026?

Hinge Health (HNGE) reported revenue of $235M for the third quarter 2026 (Q3 2026), +52% from a year earlier and +10% from the quarter before.

Was Hinge Health profitable in the third quarter 2026?

Operating profit was $50.3M (21.4% of revenue) and net earnings $57.4M.

Open the interactive Sankey →

Source: Hinge Health 8-K on SEC EDGAR.